Compound useful for the treatment of degenerative and inflammatory diseases
A pyrazolopyridine compound according to Formula I, able to inhibit JAK is disclosed, as well as pharmaceutically acceptable salts, a solvate thereof, solvates of the pharmaceutically acceptable salts and biologically active metabolites thereof. The compound may be prepared as a pharmaceutical composition, and may be used for the treatment or prophylaxis of a variety of conditions in mammals including humans, and particularly, such conditions as may be associated with aberrant JAK activity, including by way of non-limiting example, allergy, inflammatory conditions, autoimmune diseases, proliferative diseases, transplant rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of IL 6 .
1. The compound according to Formula I:
or a pharmaceutically acceptable salt, or a biologically active metabolite thereof.
2. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a pharmaceutically effective amount of the compound or pharmaceutically acceptable salt thereof, according to claim 1 .
3. The pharmaceutical composition of claim 2 , wherein the carrier is selected from a parenteral carrier, an oral carrier and a topical carrier.
4. The pharmaceutical composition according to claim 2 comprising a further therapeutic agent selected from arthritis treatment agents.
5. The pharmaceutical composition according to claim 4 , wherein the further therapeutic agent is an agent selected from analgesics, NSAIDS (non-steroidal anti-inflammatory drugs), and DMARDS (disease-modifying anti-rheumatic drugs).
6. A method for the treatment of rheumatoid arthritis, comprising administering an amount of a compound of claim 1 , sufficient to effect said treatment.
7. The method according to claim 6 , wherein said compound is administered in combination with more than one further therapeutic agents selected from arthritis treatment agents.
8. The method according to claim 6 , wherein said compound is administered in combination with one further therapeutic agent selected from arthritis treatment agents.
9. A method for the treatment of rheumatoid arthritis, comprising administering an amount of a pharmaceutical composition of claim 2 , sufficient to effect said treatment.
10. The method according to claim 7 , wherein the further therapeutic agents are selected from analgesics, NSAIDS (non-steroidal anti-inflammatory drugs), and DMARDS (disease-modifying anti-rheumatic drugs).
11. The method according to claim 8 , wherein the further therapeutic agent is an agent selected from analgesics, NSAIDS (non-steroidal anti-inflammatory drugs), and DMARDS (disease-modifying anti-rheumatic drugs).